Nivolumab and Relatlimab

BIOLOGICAL2 trials

Sponsors

TriSalus Life Sciences, Inc., University of Wisconsin, Madison

Conditions

Liver MetastasesMetastatic MelanomaMetastatic Uveal Melanoma in the Liver

Phase 1

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

TerminatedNCT04935229

TriSalus Life Sciences, Inc.Metastatic Uveal Melanoma in the Liver

Start: 2021-08-02End: 2024-07-17Updated: 2025-10-22

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

RecruitingNCT07281924

University of Wisconsin, MadisonLiver Metastases, Metastatic Melanoma

Start: 2026-04-01End: 2030-12-01Target: 15Updated: 2026-03-24

Related Papers

1534 Clinical activity of SD-101 with immune checkpoint inhibition (ICI) in metastatic uveal melanoma liver metastasis (MUM-LM) from the PERIO-01 Phase 1 trial

2023-10-314 citations

Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM).

Journal of Clinical Oncology2023-06-018 citations

Abstract 5881: PERIO-01: Initial safety experience and immunologic effects of a Class C TLR9 agonist using pressure- enabled drug delivery in a phase 1 trial of hepatic arterial infusion of SD-101 +/- checkpoint inhibition in metastatic uveal melanoma

Cancer Research2023-04-042 citations

1165 Impact of SD-101, a toll-like receptor 9 class C (TLR9C), agonist on myeloid derived suppressor cells

Regular and Young Investigator Award Abstracts2022-11-012 citations